Point72 Asset Management L.P. Has $48.97 Million Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Point72 Asset Management L.P. raised its holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 4,968.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,335,000 shares of the biotechnology company’s stock after acquiring an additional 6,210,000 shares during the quarter. Point72 Asset Management L.P. owned about 0.10% of CytomX Therapeutics worth $48,970,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of CTMX. RA Capital Management L.P. acquired a new stake in CytomX Therapeutics in the first quarter valued at approximately $27,055,000. BlackRock Inc. lifted its stake in CytomX Therapeutics by 36.4% in the first quarter. BlackRock Inc. now owns 5,188,705 shares of the biotechnology company’s stock valued at $40,109,000 after acquiring an additional 1,383,526 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in CytomX Therapeutics by 147.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,696,266 shares of the biotechnology company’s stock valued at $13,112,000 after acquiring an additional 1,009,792 shares during the last quarter. Platinum Investment Management Ltd. lifted its stake in CytomX Therapeutics by 159.0% in the first quarter. Platinum Investment Management Ltd. now owns 785,899 shares of the biotechnology company’s stock valued at $6,075,000 after acquiring an additional 482,434 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in CytomX Therapeutics by 19.5% in the first quarter. Victory Capital Management Inc. now owns 2,768,882 shares of the biotechnology company’s stock valued at $21,403,000 after acquiring an additional 451,485 shares during the last quarter. Hedge funds and other institutional investors own 83.97% of the company’s stock.

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of CytomX Therapeutics in a research report on Tuesday, July 6th. Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research report on Tuesday. Barclays lowered shares of CytomX Therapeutics from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $9.00 to $7.00 in a research report on Friday, May 28th. Finally, JPMorgan Chase & Co. assumed coverage on shares of CytomX Therapeutics in a research report on Monday, March 29th. They issued an “overweight” rating and a $14.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $9.60.

Shares of CTMX stock opened at $5.89 on Thursday. CytomX Therapeutics, Inc. has a 1 year low of $5.63 and a 1 year high of $10.05. The business’s fifty day moving average is $6.94.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, May 6th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.03. CytomX Therapeutics had a negative net margin of 90.87% and a negative return on equity of 80.13%. The business had revenue of $15.97 million for the quarter, compared to analyst estimates of $20.32 million. On average, analysts expect that CytomX Therapeutics, Inc. will post -1.09 EPS for the current fiscal year.

In other CytomX Therapeutics news, CEO Sean A. Mccarthy sold 100,000 shares of the business’s stock in a transaction on Wednesday, June 16th. The shares were sold at an average price of $7.04, for a total value of $704,000.00. Following the sale, the chief executive officer now owns 7,849 shares of the company’s stock, valued at approximately $55,256.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.80% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

Read More: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.